Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
NeoGenomics, Inc.

NeoGenomics, Inc. (NEO) Stock Overview

Explore NeoGenomics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

NEO●NASDAQ
HealthcareMedical - Diagnostics & Research
$16.98
$0.45(2.72%)
U.S. Market opens in 64h 14m

NeoGenomics, Inc. (NEO)

Meyka AI Score

Z

Key Financials

Market Cap436.3M
P/E Ratio-8.28
EPS (TTM)$0.13
ROE-0.06%
Fundamental Analysis

AI Price Forecasts

1 Month$18.84
3 Months$18.94
1 Year Target$14.25

NEO Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of NeoGenomics, Inc. (NASDAQ: NEO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, NeoGenomics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of NEO on the NASDAQ shows an RSI of 59.84, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $14.25 for the NASDAQ listing.

Key metrics behind NeoGenomics, Inc.'s NASDAQ-traded stock include a P/E ratio of -8.28 and a market capitalization of 436.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of NEO on the NASDAQ.

Price Performance (NASDAQ: NEO)

1-Day Change
2.72%
5-Day Change
3.66%
1-Month Change
17.51%
3-Month Change
86.39%
6-Month Change
71.69%
Year-to-Date (YTD) Change
44.39%
1-Year Change
174.76%
3-Year Change
20.60%
5-Year Change
-61.95%
All-Time (Max) Change
3848.84%

Contact Information

https://www.neogenomics.com
239 768 0600
9490 NeoGenomics Way, Fort Myers, FL, 33912

Company Facts

25,000 Employees
IPO DateMar 16, 2004
CountryUS
Actively Trading

Frequently Asked Questions